Pacira BioSciences, Inc. (PCRX) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $24.40 (-4.28%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 30, 2025 | Les Sulewski | Truist Financial | $25.00 | +2.5% |
| Nov 7, 2024 | David Amsellem | Piper Sandler | $12.00 | -50.8% |
| Sep 24, 2024 | Glen Santangelo | Jefferies | $18.00 | -26.2% |
| Aug 13, 2024 | Les Sulewski | Truist Financial | $8.00 | -67.2% |
| Jul 2, 2024 | Oren Livnat | H.C. Wainwright | $57.00 | +133.6% |
| Jun 13, 2024 | Glen Santangelo | Jefferies | $36.00 | +47.5% |
| May 21, 2024 | David Amsellem | Piper Sandler | $42.00 | +72.1% |
Top Analysts Covering PCRX
PCRX vs Sector & Market
| Metric | PCRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.20 | 2.24 | 2.41 |
| Analyst Count | 5 | 8 | 18 |
| Target Upside | +20.9% | +1150.2% | +14.9% |
| P/E Ratio | 206.60 | 6.68 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $189M | $190M | $192M | 4 |
| 2026-09-30 | $190M | $191M | $193M | 2 |
| 2026-12-31 | $205M | $206M | $209M | 3 |
| 2027-03-31 | $191M | $192M | $195M | 3 |
| 2027-06-30 | $202M | $204M | $206M | 2 |
| 2027-09-30 | $210M | $211M | $214M | 2 |
| 2027-12-31 | $220M | $222M | $225M | 3 |
| 2028-12-31 | $960M | $960M | $960M | 4 |
| 2029-12-31 | $912M | $923M | $940M | 3 |
| 2030-12-31 | $922M | $933M | $950M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.57 | $0.71 | $0.84 | 4 |
| 2026-09-30 | $0.68 | $0.69 | $0.70 | 1 |
| 2026-12-31 | $0.67 | $0.68 | $0.69 | 2 |
| 2027-03-31 | $0.65 | $0.66 | $0.67 | 2 |
| 2027-06-30 | $0.79 | $0.80 | $0.81 | 1 |
| 2027-09-30 | $0.84 | $0.85 | $0.87 | 1 |
| 2027-12-31 | $0.94 | $0.96 | $0.97 | 2 |
| 2028-12-31 | $4.70 | $4.77 | $4.88 | 3 |
| 2029-12-31 | $4.53 | $4.60 | $4.71 | 2 |
| 2030-12-31 | $4.87 | $4.95 | $5.07 | 2 |
Frequently Asked Questions
What is the analyst consensus for PCRX?
The consensus among 5 analysts covering Pacira BioSciences, Inc. (PCRX) is Buy with an average price target of $27.00.
What is the highest price target for PCRX?
The highest price target for PCRX is $57.00, set by Oren Livnat at H.C. Wainwright on 2024-07-02.
What is the lowest price target for PCRX?
The lowest price target for PCRX is $8.00, set by Les Sulewski at Truist Financial on 2024-08-13.
How many analysts cover PCRX?
5 analysts have issued ratings for Pacira BioSciences, Inc. in the past 12 months.
Is PCRX a buy or sell right now?
Based on 5 analyst ratings, PCRX has a consensus rating of Buy (2.20/5) with a +20.9% upside to the consensus target of $27.00.
What are the earnings estimates for PCRX?
Analysts estimate PCRX will report EPS of $0.71 for the period ending 2026-06-30, with revenue estimated at $190M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.